



Systemic Sclerosis Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	136	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Systemic Sclerosis Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Systemic Sclerosis Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Systemic Sclerosis Drug is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Systemic Sclerosis Drug is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Systemic Sclerosis Drug include GlaxoSmithKline Plc, Bayer AG, GenKyoTex S.A., Fibrocell Science, Inc., F. Hoffmann-La Roche Ltd., Digna Biotech, S.L., Daval International Limited, CSL Limited and Corbus pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Systemic Sclerosis Drug market in terms of revenue (US\$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Systemic Sclerosis Drug Market by Company

GlaxoSmithKline Plc

Bayer AG

GenKyoTex S.A.
Fibrocell Science, Inc.
F. Hoffmann-La Roche Ltd.
Digna Biotech, S.L.
Daval International Limited
CSL Limited
Corbus pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
BiOrion Technologies B.V.
BioLineRx, Ltd.
arGentis Pharmaceuticals, LLC
Angion Biomedica Corp.
Allergan Plc

Systemic Sclerosis Drug Segment by Type

ARG-201
BL-1110
BOT-191
C-82
Belimumab
Others

Systemic Sclerosis Drug Segment by Application

Clinic
Hospital
ASCs
Others

Systemic Sclerosis Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea

India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Systemic Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Sclerosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Systemic Sclerosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Systemic Sclerosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Systemic Sclerosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Systemic Sclerosis Drug Market Size (2021-2032)
 - 2.2.2 Global Systemic Sclerosis Drug Sales (2021-2032)
 - 2.2.3 Global Systemic Sclerosis Drug Market Average Price (2021-2032)
- 2.3 Systemic Sclerosis Drug by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 ARG-201
 - 2.3.3 BL-1110
 - 2.3.4 BOT-191
 - 2.3.5 C-82
 - 2.3.6 Belimumab
 - 2.3.7 Others
- 2.4 Systemic Sclerosis Drug by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Clinic
 - 2.4.3 Hospital
 - 2.4.4 ASCs
 - 2.4.5 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Systemic Sclerosis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Systemic Sclerosis Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Systemic Sclerosis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Systemic Sclerosis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Systemic Sclerosis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Systemic Sclerosis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Systemic Sclerosis Drug, Product Type & Application
- 3.8 Global Manufacturers of Systemic Sclerosis Drug, Established Date
- 3.9 Global Systemic Sclerosis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 GlaxoSmithKline Plc
 - 4.1.1 GlaxoSmithKline Plc Company Information
 - 4.1.2 GlaxoSmithKline Plc Business Overview

- 4.1.3 GlaxoSmithKline Plc Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolio
- 4.1.5 GlaxoSmithKline Plc Recent Developments
- 4.2 Bayer AG
 - 4.2.1 Bayer AG Company Information
 - 4.2.2 Bayer AG Business Overview
 - 4.2.3 Bayer AG Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Bayer AG Systemic Sclerosis Drug Product Portfolio
 - 4.2.5 Bayer AG Recent Developments
- 4.3 GenKyoTex S.A.
 - 4.3.1 GenKyoTex S.A. Company Information
 - 4.3.2 GenKyoTex S.A. Business Overview
 - 4.3.3 GenKyoTex S.A. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolio
 - 4.3.5 GenKyoTex S.A. Recent Developments
- 4.4 Fibrocell Science, Inc.
 - 4.4.1 Fibrocell Science, Inc. Company Information
 - 4.4.2 Fibrocell Science, Inc. Business Overview
 - 4.4.3 Fibrocell Science, Inc. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolio
 - 4.4.5 Fibrocell Science, Inc. Recent Developments
- 4.5 F. Hoffmann-La Roche Ltd.
 - 4.5.1 F. Hoffmann-La Roche Ltd. Company Information
 - 4.5.2 F. Hoffmann-La Roche Ltd. Business Overview
 - 4.5.3 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolio
 - 4.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.6 Digna Biotech, S.L.
 - 4.6.1 Digna Biotech, S.L. Company Information
 - 4.6.2 Digna Biotech, S.L. Business Overview
 - 4.6.3 Digna Biotech, S.L. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolio
 - 4.6.5 Digna Biotech, S.L. Recent Developments
- 4.7 Daval International Limited
 - 4.7.1 Daval International Limited Company Information
 - 4.7.2 Daval International Limited Business Overview
 - 4.7.3 Daval International Limited Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Daval International Limited Systemic Sclerosis Drug Product Portfolio
 - 4.7.5 Daval International Limited Recent Developments
- 4.8 CSL Limited
 - 4.8.1 CSL Limited Company Information
 - 4.8.2 CSL Limited Business Overview
 - 4.8.3 CSL Limited Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 CSL Limited Systemic Sclerosis Drug Product Portfolio
 - 4.8.5 CSL Limited Recent Developments
- 4.9 Corbus pharmaceuticals, Inc.
 - 4.9.1 Corbus pharmaceuticals, Inc. Company Information
 - 4.9.2 Corbus pharmaceuticals, Inc. Business Overview

- 4.9.3 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolio
- 4.9.5 Corbus pharmaceuticals, Inc. Recent Developments
- 4.10 Bristol-Myers Squibb Company
 - 4.10.1 Bristol-Myers Squibb Company Company Information
 - 4.10.2 Bristol-Myers Squibb Company Business Overview
 - 4.10.3 Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.10.4 Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolio
 - 4.10.5 Bristol-Myers Squibb Company Recent Developments
- 4.11 Boehringer Ingelheim GmbH
 - 4.11.1 Boehringer Ingelheim GmbH Company Information
 - 4.11.2 Boehringer Ingelheim GmbH Business Overview
 - 4.11.3 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.11.4 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolio
 - 4.11.5 Boehringer Ingelheim GmbH Recent Developments
- 4.12 BiOrion Technologies B.V.
 - 4.12.1 BiOrion Technologies B.V. Company Information
 - 4.12.2 BiOrion Technologies B.V. Business Overview
 - 4.12.3 BiOrion Technologies B.V. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.12.4 BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolio
 - 4.12.5 BiOrion Technologies B.V. Recent Developments
- 4.13 BioLineRx, Ltd.
 - 4.13.1 BioLineRx, Ltd. Company Information
 - 4.13.2 BioLineRx, Ltd. Business Overview
 - 4.13.3 BioLineRx, Ltd. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.13.4 BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolio
 - 4.13.5 BioLineRx, Ltd. Recent Developments
- 4.14 arGentis Pharmaceuticals, LLC
 - 4.14.1 arGentis Pharmaceuticals, LLC Company Information
 - 4.14.2 arGentis Pharmaceuticals, LLC Business Overview
 - 4.14.3 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.14.4 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolio
 - 4.14.5 arGentis Pharmaceuticals, LLC Recent Developments
- 4.15 Angion Biomedica Corp.
 - 4.15.1 Angion Biomedica Corp. Company Information
 - 4.15.2 Angion Biomedica Corp. Business Overview
 - 4.15.3 Angion Biomedica Corp. Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.15.4 Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolio
 - 4.15.5 Angion Biomedica Corp. Recent Developments
- 4.16 Allergan Plc
 - 4.16.1 Allergan Plc Company Information
 - 4.16.2 Allergan Plc Business Overview
 - 4.16.3 Allergan Plc Systemic Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.16.4 Allergan Plc Systemic Sclerosis Drug Product Portfolio
 - 4.16.5 Allergan Plc Recent Developments

5 Global Systemic Sclerosis Drug Market Scenario by Region

- 5.1 Global Systemic Sclerosis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Systemic Sclerosis Drug Sales by Region: 2021-2032

- 5.2.1 Global Systemic Sclerosis Drug Sales by Region: 2021-2026
- 5.2.2 Global Systemic Sclerosis Drug Sales by Region: 2027-2032
- 5.3 Global Systemic Sclerosis Drug Revenue by Region: 2021-2032
 - 5.3.1 Global Systemic Sclerosis Drug Revenue by Region: 2021-2026
 - 5.3.2 Global Systemic Sclerosis Drug Revenue by Region: 2027-2032
- 5.4 North America Systemic Sclerosis Drug Market Facts & Figures by Country
 - 5.4.1 North America Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Systemic Sclerosis Drug Sales by Country (2021-2032)
 - 5.4.3 North America Systemic Sclerosis Drug Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Systemic Sclerosis Drug Market Facts & Figures by Country
 - 5.5.1 Europe Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Systemic Sclerosis Drug Sales by Country (2021-2032)
 - 5.5.3 Europe Systemic Sclerosis Drug Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia
 - 5.5.9 Spain
 - 5.5.10 Netherlands
 - 5.5.11 Switzerland
 - 5.5.12 Sweden
 - 5.5.13 Poland
- 5.6 Asia Pacific Systemic Sclerosis Drug Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Systemic Sclerosis Drug Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Systemic Sclerosis Drug Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America Systemic Sclerosis Drug Market Facts & Figures by Country
 - 5.7.1 South America Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Systemic Sclerosis Drug Sales by Country (2021-2032)
 - 5.7.3 South America Systemic Sclerosis Drug Revenue by Country (2021-2032)
 - 5.7.4 Brazil
 - 5.7.5 Argentina
 - 5.7.6 Chile
- 5.8 Middle East and Africa Systemic Sclerosis Drug Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa Systemic Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.8.2 Middle East and Africa Systemic Sclerosis Drug Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa Systemic Sclerosis Drug Revenue by Country (2021-2032)

- 5.8.4 Egypt
 - 5.8.5 South Africa
 - 5.8.6 Israel
 - 5.8.7 Türkiye
 - 5.8.8 GCC Countries
-

6 Segment by Type

- 6.1 Global Systemic Sclerosis Drug Sales by Type (2021-2032)
 - 6.1.1 Global Systemic Sclerosis Drug Sales by Type (2021-2032) & (W Units)
 - 6.1.2 Global Systemic Sclerosis Drug Sales Market Share by Type (2021-2032)
 - 6.2 Global Systemic Sclerosis Drug Revenue by Type (2021-2032)
 - 6.2.1 Global Systemic Sclerosis Drug Sales by Type (2021-2032) & (US\$ Million)
 - 6.2.2 Global Systemic Sclerosis Drug Revenue Market Share by Type (2021-2032)
 - 6.3 Global Systemic Sclerosis Drug Price by Type (2021-2032)
-

7 Segment by Application

- 7.1 Global Systemic Sclerosis Drug Sales by Application (2021-2032)
 - 7.1.1 Global Systemic Sclerosis Drug Sales by Application (2021-2032) & (W Units)
 - 7.1.2 Global Systemic Sclerosis Drug Sales Market Share by Application (2021-2032)
 - 7.2 Global Systemic Sclerosis Drug Revenue by Application (2021-2032)
 - 7.2.1 Global Systemic Sclerosis Drug Sales by Application (2021-2032) & (US\$ Million)
 - 7.2.2 Global Systemic Sclerosis Drug Revenue Market Share by Application (2021-2032)
 - 7.3 Global Systemic Sclerosis Drug Price by Application (2021-2032)
-

8 Value Chain and Sales Channels Analysis of the Market

- 8.1 Systemic Sclerosis Drug Value Chain Analysis
 - 8.1.1 Systemic Sclerosis Drug Key Raw Materials
 - 8.1.2 Raw Materials Key Suppliers
 - 8.1.3 Systemic Sclerosis Drug Production Mode & Process
 - 8.2 Systemic Sclerosis Drug Sales Channels Analysis
 - 8.2.1 Direct Comparison with Distribution Share
 - 8.2.2 Systemic Sclerosis Drug Distributors
 - 8.2.3 Systemic Sclerosis Drug Customers
-

9 Global Systemic Sclerosis Drug Analyzing Market Dynamics

- 9.1 Systemic Sclerosis Drug Industry Trends
 - 9.2 Systemic Sclerosis Drug Industry Drivers
 - 9.3 Systemic Sclerosis Drug Industry Opportunities and Challenges
 - 9.4 Systemic Sclerosis Drug Industry Restraints
-

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Systemic Sclerosis Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Systemic Sclerosis Drug Sales (W Units) of Manufacturers (2021-2026)
- Table 7: Global Systemic Sclerosis Drug Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Systemic Sclerosis Drug Revenue of Manufacturers (2021-2026)
- Table 9: Global Systemic Sclerosis Drug Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Systemic Sclerosis Drug Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Systemic Sclerosis Drug Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Systemic Sclerosis Drug, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Systemic Sclerosis Drug, Product Type & Application
- Table 14: Global Systemic Sclerosis Drug Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Systemic Sclerosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: GlaxoSmithKline Plc Company Information
- Table 19: GlaxoSmithKline Plc Business Overview
- Table 20: GlaxoSmithKline Plc Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolio
- Table 22: GlaxoSmithKline Plc Recent Developments
- Table 23: Bayer AG Company Information
- Table 24: Bayer AG Business Overview
- Table 25: Bayer AG Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Bayer AG Systemic Sclerosis Drug Product Portfolio
- Table 27: Bayer AG Recent Developments
- Table 28: GenKyoTex S.A. Company Information
- Table 29: GenKyoTex S.A. Business Overview
- Table 30: GenKyoTex S.A. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolio
- Table 32: GenKyoTex S.A. Recent Developments
- Table 33: Fibrocell Science, Inc. Company Information
- Table 34: Fibrocell Science, Inc. Business Overview
- Table 35: Fibrocell Science, Inc. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolio
- Table 37: Fibrocell Science, Inc. Recent Developments
- Table 38: F. Hoffmann-La Roche Ltd. Company Information
- Table 39: F. Hoffmann-La Roche Ltd. Business Overview
- Table 40: F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolio
- Table 42: F. Hoffmann-La Roche Ltd. Recent Developments
- Table 43: Digna Biotech, S.L. Company Information
- Table 44: Digna Biotech, S.L. Business Overview
- Table 45: Digna Biotech, S.L. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolio
- Table 47: Digna Biotech, S.L. Recent Developments
- Table 48: Daval International Limited Company Information
- Table 49: Daval International Limited Business Overview

- Table 50: Daval International Limited Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: Daval International Limited Systemic Sclerosis Drug Product Portfolio
- Table 52: Daval International Limited Recent Developments
- Table 53: CSL Limited Company Information
- Table 54: CSL Limited Business Overview
- Table 55: CSL Limited Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 56: CSL Limited Systemic Sclerosis Drug Product Portfolio
- Table 57: CSL Limited Recent Developments
- Table 58: Corbus pharmaceuticals, Inc. Company Information
- Table 59: Corbus pharmaceuticals, Inc. Business Overview
- Table 60: Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 61: Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolio
- Table 62: Corbus pharmaceuticals, Inc. Recent Developments
- Table 63: Bristol-Myers Squibb Company Company Information
- Table 64: Bristol-Myers Squibb Company Business Overview
- Table 65: Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 66: Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolio
- Table 67: Bristol-Myers Squibb Company Recent Developments
- Table 68: Boehringer Ingelheim GmbH Company Information
- Table 69: Boehringer Ingelheim GmbH Business Overview
- Table 70: Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 71: Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolio
- Table 72: Boehringer Ingelheim GmbH Recent Developments
- Table 73: BiOrion Technologies B.V. Company Information
- Table 74: BiOrion Technologies B.V. Business Overview
- Table 75: BiOrion Technologies B.V. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 76: BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolio
- Table 77: BiOrion Technologies B.V. Recent Developments
- Table 78: BioLineRx, Ltd. Company Information
- Table 79: BioLineRx, Ltd. Business Overview
- Table 80: BioLineRx, Ltd. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 81: BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolio
- Table 82: BioLineRx, Ltd. Recent Developments
- Table 83: arGentis Pharmaceuticals, LLC Company Information
- Table 84: arGentis Pharmaceuticals, LLC Business Overview
- Table 85: arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 86: arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolio
- Table 87: arGentis Pharmaceuticals, LLC Recent Developments
- Table 88: Angion Biomedica Corp. Company Information
- Table 89: Angion Biomedica Corp. Business Overview
- Table 90: Angion Biomedica Corp. Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 91: Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolio
- Table 92: Angion Biomedica Corp. Recent Developments
- Table 93: Allergan Plc Company Information
- Table 94: Allergan Plc Business Overview
- Table 95: Allergan Plc Systemic Sclerosis Drug Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 96: Allergan Plc Systemic Sclerosis Drug Product Portfolio
- Table 97: Allergan Plc Recent Developments
- Table 98: Global Systemic Sclerosis Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 99: Global Systemic Sclerosis Drug Sales by Region (2021-2026) & (W Units)
- Table 100: Global Systemic Sclerosis Drug Sales Market Share by Region (2021-2026)
- Table 101: Global Systemic Sclerosis Drug Sales by Region (2027-2032) & (W Units)
- Table 102: Global Systemic Sclerosis Drug Sales Market Share by Region (2027-2032)
- Table 103: Global Systemic Sclerosis Drug Revenue by Region (2021-2026) & (US\$ Million)
- Table 104: Global Systemic Sclerosis Drug Revenue Market Share by Region (2021-2026)

- Table 105: Global Systemic Sclerosis Drug Revenue by Region (2027-2032) & (US\$ Million)
- Table 106: Global Systemic Sclerosis Drug Revenue Market Share by Region (2027-2032)
- Table 107: North America Systemic Sclerosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 108: North America Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units)
- Table 109: North America Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units)
- Table 110: North America Systemic Sclerosis Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 111: North America Systemic Sclerosis Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 112: Europe Systemic Sclerosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 113: Europe Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units)
- Table 114: Europe Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units)
- Table 115: Europe Systemic Sclerosis Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 116: Europe Systemic Sclerosis Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 117: Asia Pacific Systemic Sclerosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 118: Asia Pacific Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units)
- Table 119: Asia Pacific Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units)
- Table 120: Asia Pacific Systemic Sclerosis Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 121: Asia Pacific Systemic Sclerosis Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 122: South America Systemic Sclerosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 123: South America Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units)
- Table 124: South America Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units)
- Table 125: South America Systemic Sclerosis Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 126: South America Systemic Sclerosis Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 127: Middle East and Africa Systemic Sclerosis Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 128: Middle East and Africa Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units)
- Table 129: Middle East and Africa Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units)
- Table 130: Middle East and Africa Systemic Sclerosis Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 131: Middle East and Africa Systemic Sclerosis Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 132: Global Systemic Sclerosis Drug Sales by Type (2021-2026) & (W Units)
- Table 133: Global Systemic Sclerosis Drug Sales by Type (2027-2032) & (W Units)
- Table 134: Global Systemic Sclerosis Drug Sales Market Share by Type (2021-2026)
- Table 135: Global Systemic Sclerosis Drug Sales Market Share by Type (2027-2032)
- Table 136: Global Systemic Sclerosis Drug Revenue by Type (2021-2026) & (US\$ Million)
- Table 137: Global Systemic Sclerosis Drug Revenue by Type (2027-2032) & (US\$ Million)
- Table 138: Global Systemic Sclerosis Drug Revenue Market Share by Type (2021-2026)
- Table 139: Global Systemic Sclerosis Drug Revenue Market Share by Type (2027-2032)
- Table 140: Global Systemic Sclerosis Drug Price by Type (2021-2026) & (US\$/Unit)
- Table 141: Global Systemic Sclerosis Drug Price by Type (2027-2032) & (US\$/Unit)
- Table 142: Global Systemic Sclerosis Drug Sales by Application (2021-2026) & (W Units)
- Table 143: Global Systemic Sclerosis Drug Sales by Application (2027-2032) & (W Units)
- Table 144: Global Systemic Sclerosis Drug Sales Market Share by Application (2021-2026)
- Table 145: Global Systemic Sclerosis Drug Sales Market Share by Application (2027-2032)
- Table 146: Global Systemic Sclerosis Drug Revenue by Application (2021-2026) & (US\$ Million)
- Table 147: Global Systemic Sclerosis Drug Revenue by Application (2027-2032) & (US\$ Million)
- Table 148: Global Systemic Sclerosis Drug Revenue Market Share by Application (2021-2026)
- Table 149: Global Systemic Sclerosis Drug Revenue Market Share by Application (2027-2032)
- Table 150: Global Systemic Sclerosis Drug Price by Application (2021-2026) & (US\$/Unit)
- Table 151: Global Systemic Sclerosis Drug Price by Application (2027-2032) & (US\$/Unit)
- Table 152: Key Raw Materials
- Table 153: Raw Materials Key Suppliers
- Table 154: Systemic Sclerosis Drug Distributors List
- Table 155: Systemic Sclerosis Drug Customers List
- Table 156: Systemic Sclerosis Drug Industry Trends
- Table 157: Systemic Sclerosis Drug Industry Drivers
- Table 158: Systemic Sclerosis Drug Industry Restraints
- Table 159: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Systemic Sclerosis Drug Product Image
- Figure 5: Global Systemic Sclerosis Drug Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Systemic Sclerosis Drug Market Size (2021-2032) & (US\$ Million)

- Figure 7: Global Systemic Sclerosis Drug Sales (2021-2032) & (W Units)
- Figure 8: Global Systemic Sclerosis Drug Average Price (US\$/Unit) & (2021-2032)
- Figure 9: ARG-201 Product Image
- Figure 10: BL-1110 Product Image
- Figure 11: BOT-191 Product Image
- Figure 12: C-82 Product Image
- Figure 13: Belimumab Product Image
- Figure 14: Others Product Image
- Figure 15: Clinic Product Image
- Figure 16: Hospital Product Image
- Figure 17: ASCs Product Image
- Figure 18: Others Product Image
- Figure 19: Global Systemic Sclerosis Drug Revenue Share by Manufacturers in 2025
- Figure 20: Global Manufacturers of Systemic Sclerosis Drug, Manufacturing Sites & Headquarters
- Figure 21: Global Top 5 and 10 Systemic Sclerosis Drug Players Market Share by Revenue in 2025
- Figure 22: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: Global Systemic Sclerosis Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 24: Global Systemic Sclerosis Drug Sales by Region in 2025
- Figure 25: Global Systemic Sclerosis Drug Revenue by Region in 2025
- Figure 26: North America Systemic Sclerosis Drug Market Size by Country in 2025
- Figure 27: North America Systemic Sclerosis Drug Sales Market Share by Country (2021-2032)
- Figure 28: North America Systemic Sclerosis Drug Revenue Market Share by Country (2021-2032)
- Figure 29: United States Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Canada Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: Mexico Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: Europe Systemic Sclerosis Drug Market Size by Country in 2025
- Figure 33: Europe Systemic Sclerosis Drug Sales Market Share by Country (2021-2032)
- Figure 34: Europe Systemic Sclerosis Drug Revenue Market Share by Country (2021-2032)
- Figure 35: Germany Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: France Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: U.K. Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Italy Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Russia Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Spain Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Netherlands Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Switzerland Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Sweden Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Poland Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: Asia Pacific Systemic Sclerosis Drug Market Size by Country in 2025
- Figure 46: Asia Pacific Systemic Sclerosis Drug Sales Market Share by Country (2021-2032)
- Figure 47: Asia Pacific Systemic Sclerosis Drug Revenue Market Share by Country (2021-2032)
- Figure 48: China Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Japan Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: South Korea Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: India Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Australia Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: Taiwan Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: Southeast Asia Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 55: Southeast Asia Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: South America Systemic Sclerosis Drug Market Size by Country in 2025
- Figure 57: South America Systemic Sclerosis Drug Sales Market Share by Country (2021-2032)
- Figure 58: South America Systemic Sclerosis Drug Revenue Market Share by Country (2021-2032)
- Figure 59: Brazil Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Argentina Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: Chile Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 62: Middle East and Africa Systemic Sclerosis Drug Market Size by Country in 2025
- Figure 63: Middle East and Africa Systemic Sclerosis Drug Sales Market Share by Country (2021-2032)
- Figure 64: Middle East and Africa Systemic Sclerosis Drug Revenue Market Share by Country (2021-2032)
- Figure 65: Egypt Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: South Africa Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Israel Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 68: Türkiye Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 69: GCC Countries Systemic Sclerosis Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 70: Global Systemic Sclerosis Drug Sales Market Share by Type (2021-2032)
- Figure 71: Global Systemic Sclerosis Drug Revenue Market Share by Type (2021-2032)

- Figure 72: Global Systemic Sclerosis Drug Price (US\$/Unit) by Type (2021-2032)
- Figure 73: Global Systemic Sclerosis Drug Sales Market Share by Application (2021-2032)
- Figure 74: Global Systemic Sclerosis Drug Revenue Market Share by Application (2021-2032)
- Figure 75: Global Systemic Sclerosis Drug Price (US\$/Unit) by Application (2021-2032)
- Figure 76: Systemic Sclerosis Drug Value Chain
- Figure 77: Systemic Sclerosis Drug Production Mode & Process
- Figure 78: Direct Comparison with Distribution Share
- Figure 79: Distributors Profiles
- Figure 80: Systemic Sclerosis Drug Industry Opportunities and Challenges